Dupilumab with Topical Corticosteroids Provides Rapid and Sustained Improvement in Adults with Moderate-to-Severe Atopic Dermatitis Across Anatomic Regions Over 52 Weeks

por Blauvelt, Andrew, de Bruin-Weller, Marjolein, Simpson, Eric L., Chen, Zhen, Zhang, Annie, Shumel, Brad
Publicado 2021

Dupilumab Maintains Long-Term Disease Control in Adults with Moderate-to-Severe Atopic Dermatitis as Measured by Well-Controlled Weeks: Results From the LIBERTY AD CHRONOS Clinical...

por Wu, Jashin J., Spelman, Lynda, Tan, Jerry L., Etoh, Takafumi, Zhang, Haixin, Shumel, Brad, Rossi, Ana B.
Publicado 2021

Patient-Reported Ocular Disorders and Symptoms in Adults with Moderate-to-Severe Atopic Dermatitis: Screening and Baseline Survey Data from a Clinical Trial

por Weyne, Jonathan, Blauvelt, Andrew, de Bruin-Weller, Marjolein, Prens, Errol, Asbell, Penny, Sierka, Debra, Chen, Zhen, Shumel, Brad
Publicado 2020

Base and Covariate Population Pharmacokinetic Analyses of Dupilumab in Adolescents and Children ≥6 to <12 Years of Age Using Phase 3 Data

por Kovalenko, Pavel, Kamal, Mohamed A., Davis, John D., Huniti, Nidal, Xu, Christine, Bansal, Ashish, Shumel, Brad, DiCioccio, A. Thomas
Publicado 2021

Base and Covariate Population Pharmacokinetic Analyses of Dupilumab Using Phase 3 Data

por Kovalenko, Pavel, Davis, John D., Li, Meng, Rippley, Ronda, Ardeleanu, Marius, Shumel, Brad, Graham, Neil M.H., Pirozzi, Gianluca, Kamal, Mohamed A., DiCioccio, A. Thomas
Publicado 2020

Dupilumab Provides Rapid and Sustained Clinically Meaningful Responses in Adults with Moderate-to-severe Atopic Dermatitis

por SILVERBERG, Jonathan I., SIMPSON, Eric L., BOGUNIEWICZ, Mark, DE BRUIN-WELLER, Marjolein S., FOLEY, Peter, KATAOKA, Yoko, BÉGO-LE BAGOUSSE, Gaëlle, CHEN, Zhen, SHUMEL, Brad, CHAO, Jingdong, ROSSI, Ana B.
Publicado 2021

Long-Term Effectiveness of Dupilumab in Patients with Atopic Dermatitis: Results up to 3 Years from the RELIEVE-AD Study

por Kimball, Alexa B., Delevry, Dimittri, Yang, Min, Chuang, Chien-Chia, Wang, Zhixiao, Bégo-Le-Bagousse, Gaëlle, Martins, Bruno, Wu, Eric, Shumel, Brad, Wang, Jessie, Sierka, Debra, Chao, Jingdong, Strober, Bruce
Publicado 2023

Dupilumab Demonstrates Rapid and Consistent Improvement in Extent and Signs of Atopic Dermatitis Across All Anatomical Regions in Pediatric Patients 6 Years of Age and Older

por Simpson, Eric L., Paller, Amy S., Siegfried, Elaine C., Thaçi, Diamant, Wollenberg, Andreas, Cork, Michael J., Marcoux, Danielle, Huang, Rui, Chen, Zhen, Rossi, Ana B., Shumel, Brad, Sierka, Debra, Bansal, Ashish
Publicado 2021

Dupilumab Treatment Provides Sustained Improvements Over 2 Years in Symptoms and Quality of Life in Adults with Atopic Dermatitis

por Yosipovitch, Gil, de Bruin-Weller, Marjolein, Armstrong, April, Wu, Jashin J., Herranz, Pedro, Thaçi, Diamant, Delevry, Dimittri, Bagousse, Gaëlle Bégo-Le, Zhang, Raymond, Shumel, Brad, Rossi, Ana B., Chao, Jingdong
Publicado 2021

Continued Treatment with Dupilumab is Associated with Improved Efficacy in Adults with Moderate-to-Severe Atopic Dermatitis Not Achieving Optimal Responses with Short-Term Treatmen...

por Armstrong, April, Blauvelt, Andrew, Simpson, Eric L., Smith, Catherine H., Herranz, Pedro, Kataoka, Yoko, Seo, Seong Jun, Ferrucci, Silvia M., Chao, Jingdong, Chen, Zhen, Rossi, Ana B., Shumel, Brad, Tomondy, Paul
Publicado 2021

Dupilumab suppresses type 2 inflammatory biomarkers across multiple atopic, allergic diseases

por Hamilton, Jennifer D., Harel, Sivan, Swanson, Brian N., Brian, William, Chen, Zhen, Rice, Megan S., Amin, Nikhil, Ardeleanu, Marius, Radin, Allen, Shumel, Brad, Ruddy, Marcella, Patel, Naimish, Pirozzi, Gianluca, Mannent, Leda, Graham, Neil M. H.
Publicado 2021

Laboratory Safety of Dupilumab in Patients Aged 6–11 Years with Severe Atopic Dermatitis: Results from a Phase III Clinical Trial

por Paller, Amy S., Wollenberg, Andreas, Siegfried, Elaine, Thaçi, Diamant, Cork, Michael J., Arkwright, Peter D., Gooderham, Melinda, Sun, Xian, O’Malley, John T., Khokhar, Faisal A., Vakil, Jignesh, Bansal, Ashish, Rosner, Karli, Shumel, Brad, Levit, Noah A.
Publicado 2021

Dupilumab Provides Favorable Safety and Sustained Efficacy for up to 3 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis

por Beck, Lisa A., Thaçi, Diamant, Deleuran, Mette, Blauvelt, Andrew, Bissonnette, Robert, de Bruin-Weller, Marjolein, Hide, Michihiro, Sher, Lawrence, Hussain, Iftikhar, Chen, Zhen, Khokhar, Faisal A., Beazley, Bethany, Ruddy, Marcella, Patel, Naimish, Graham, Neil M. H., Ardeleanu, Marius, Shumel, Brad
Publicado 2020

The Posology of Dupilumab in Pediatric Patients With Atopic Dermatitis

por Kamal, Mohamed A., Kovalenko, Pavel, Kosloski, Matthew P., Srinivasan, Kamal, Zhang, Yi, Rajadhyaksha, Manoj, Lai, Ching‐Ha, Kanamaluru, Vanaja, Xu, Christine, Sun, Xian, Simpson, Eric L., Paller, Amy S., Siegfried, Elaine C., Shumel, Brad, Bansal, Ashish, Al‐Huniti, Nidal, Davis, John D.
Publicado 2021

Dupilumab Significantly Modulates Pain and Discomfort in Patients With Atopic Dermatitis: A Post Hoc Analysis of 5 Randomized Clinical Trials

por Silverberg, Jonathan I., Simpson, Eric L., Guttman-Yassky, Emma, Cork, Michael J., de Bruin-Weller, Marjolein, Yosipovitch, Gil, Eckert, Laurent, Chen, Zhen, Ardeleanu, Marius, Shumel, Brad, Hultsch, Thomas, Rossi, Ana B., Hamilton, Jennifer D., Orengo, Jamie M., Ruddy, Marcella, Graham, Neil M. H., Pirozzi, Gianluca, Gadkari, Abhijit
Publicado 2021

Conjunctivitis in Dupilumab Clinical Trials for Adolescents with Atopic Dermatitis or Asthma

por Bansal, Ashish, Simpson, Eric L., Paller, Amy S., Siegfried, Elaine C., Blauvelt, Andrew, de Bruin-Weller, Marjolein, Corren, Jonathan, Sher, Lawrence, Guttman-Yassky, Emma, Chen, Zhen, Daizadeh, Nadia, Kamal, Mohamed A., Shumel, Brad, Mina-Osorio, Paola, Mannent, Leda, Patel, Naimish, Graham, Neil M. H., Khokhar, Faisal A., Ardeleanu, Marius
Publicado 2021